Antiarrhythmic and Cardioprotective Effects of Atorvastatin Versus Magnesium Sulfate in Cardiac Valve Replacement Surgery

• Status: Unknown status
• Trial end date: 2018-02-01
• Target enrollment: 0
• Participant gender: All

Summary

This study aims to compare the antiarrhythmic and cardioprotective effects of Atorvastatin versus Magnesium Sulfate after Cardiac valve Replacement Surgery

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Assiut University
• Treatments: Anti-Arrhythmia Agents; Atorvastatin; Atorvastatin Calcium; Magnesium Sulfate

Criteria

Inclusion Criteria:

• Patients undergoing isolated valvular replacement surgery.

• Preoperative rhythm: Sinus rhythm.

• Preoperative troponin I < 0.01 ng/mL.

• Normal lipid profile.

• White blood cells (4-11 X 103/mm3).

• Preoperative C-reactive protein < 3 mg/L.

Exclusion Criteria:

• History of atrial fibrillation.

• Any degree of heart block or patients with implanted pacemaker.

• Prior use of Antiarrhythmic drugs.

• Preoperative lipid lowering therapy (e.g statins) during the last 3 months.

• Previous treatment with any type of magnesium containing supplementation (the week before the intervention).

• Underlying heart failure or Left ventricular ejection fraction < 0.3.

• Previous myocardial infarction.

• Diabetes or other metabolic disorders.

• Renal diseases.

• Hepatic dysfunction.

• Underlying thyroid problems (hypo/hyperthyroidism).

• Underlying inflammatory disease (active or controlled)

• Immunosuppressive and anti-inflammatory medications for the treatment of coexisting conditions.

• Psychological disorders,

• Emergency cardiac surgery